Skip to main content
Toggle navigation
Search
Home
Home
Browse by Poster Presenter
Browse by Poster Presenter
Type here to filter the list
All
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
W
Wagner, John
Koneksa Health
PII-003
-
COMPLIANCE, USABILITY, RELIABILITY, AND CONSTRUCT VALIDITY OF SELF-ADMINISTERED DIGITAL MEASURES DERIVED FROM MDS-UPDRS PARTS 2 AND 3 IN AN OBSERVATIONAL STUDY TO EVALUATE PARKINSON'S DISEASE (PD) PROGRESSION: INTERIM ANALYSIS.
John Wagner
Favorite
Walton, Mollie
Children's Mercy Hospital
PII-120
-
MARFAN: MAXIMIZING ATENOLOL RESPONSE THROUGH FUNCTIONAL ASSESSMENT INVESITGATIONS AMONGST CONNECTIVE TISSUE DISORDERS
Mollie Walton
Favorite
Wang, Hechuan
Pfizer, Inc.
PII-039
-
THE EFFECT OF CARBAMAZEPINE ON THE PHARMACOKINETICS (PK) OF VEPDEGESTRANT, A PROTEOLYSIS TARGETING CHIMERA (PROTAC) ESTROGEN RECEPTOR (ER) DEGRADER IN HEALTHY ADULTS.
Hechuan Wang
Favorite
Wang, Lei
The Ohio State University
PI-115
-
THE MATERNAL AND PEDIATRIC PRECISION IN THERAPEUTIC (MPRINT) KNOWLEDGEBASE PORTAL: A POWERFUL INFRASTRUCTURE FOR MATERNAL AND PEDIATRIC PRECISION THERAPEUTICS RESEARCH
Lei Wang
Favorite
wang, lujing
Bristol Myers Squibb
PII-104
-
UTILIZING A MINIMAL PBPK (MPBPK) MODEL TO PREDICT INTRA-TUMORAL CONCENTRATIONS OF MONOCLONAL ANTIBODIES.
lujing wang
Favorite
Wang, Meijie
Mayo Clinic
PI-044
-
DISRUPTING THE PD-L1 AND PDS5B INTERACTION BY COMPOUNDS: A PROMISING THERAPEUTIC STRATEGY FOR TRIPLE-NEGATIVE BREAST CANCER.
Meijie Wang
Favorite
Wang, Shirley
University of Waterloo
PT-015
-
ADVANCEMENTS IN PEDIATRIC PHYSIOLOGICALLY-BASED PHARMACOKINETIC (PBPK) MODELING OF DRUGS IN LACTATION FOR GUIDING NEONATAL EXPOSURE RISK ASSESSMENT
Shirley Wang
Favorite
PWI-003
-
ADVANCEMENTS IN PEDIATRIC PHYSIOLOGICALLY-BASED PHARMACOKINETIC (PBPK) MODELING OF DRUGS IN LACTATION FOR GUIDING NEONATAL EXPOSURE RISK ASSESSMENT
Shirley Wang
Favorite
wang, xue
Mayo Clinic
PII-045
-
DNA METHYLTRANSFERASE INHIBITORS REDUCE TRIPLE NEGATIVE BREAST CANCER CELL GROWTH THROUGH ENHANCED IMMUNE RESPONSE BY DOWNREGULATION OF ZNF101
xue wang
Favorite
Wickramasinghe, Charuka
Karmanos Cancer Institute
PI-085
-
POPULATION PHARMACOKINETIC MODEL OF TOTAL AND UNBOUND PAMIPARIB, A PARP INHIBITOR, IN GLIOBLASTOMA PATIENTS
Charuka Wickramasinghe
Favorite
PII-103
-
SPATIALCNS-PBPK: AN R/SHINY WEB-BASED PLATFORM FOR PHYSIOLOGICALLY BASED PHARMACOKINETIC MODELING OF SPATIAL PHARMACOKINETICS IN THE HUMAN CENTRAL NERVOUS SYSTEM AND BRAIN TUMORS
Charuka Wickramasinghe
Favorite
Wilbaux, Melanie
Pumas-AI, inc.
PII-074
-
MODEL INFORMED DOSE OPTIMIZATION OF BALSTILIMAB TO SUPPORT FIXED DOSING ALONE AND IN COMBINATION WITH BOTENSILIMAB IN PATIENTS WITH SOLID TUMORS.
Melanie Wilbaux
Favorite
Williams, Jonathan
Longboard Pharmaceuticals
PII-073
-
MASS BALANCE, METABOLISM, AND EXCRETION OF [14C] BEXICASERIN IN A SINGLE DOSE RADIOLABEL STUDY IN HEALTHY ADULT MALES.
Jonathan Williams
Favorite
Wu, Fang
U.S. Food and Drug Administration
PII-099
-
PBPK MODELING TO PREDICT THE EFFECT OF GASTRIC PH ON BIOEQUIVALENCE OF PALBOCICLIB TABLETS
Fang Wu
Favorite
Wu, Liviawati
Jazz Pharmaceuticals
PI-074
-
MODEL-BASED DRUG DEVELOPMENT CONSIDERATIONS: ZANIDATAMAB IN PATIENTS WITH HER2 EXPRESSING BILIARY TRACT CANCER (BTC)
Liviawati Wu
Favorite
Wu, Yanting
Division of Clinical Pharmacology, Indiana University School of Medicine
PII-115
-
A SIMPLE AND SENSITIVE ULTRA-HIGH PERFORMANCE LIQUID CHROMATOGRAPHY TANDEM MASS SPECTROMETRY (UHPLC-MS/MS) ASSAY TO QUANTIFY TIZANIDINE AND ITS METABOLITES IN HUMAN PLASMA
Yanting Wu
Favorite
PII-118
-
EFAVIRENZ ALTERS THE DISPOSITION AND PHARMACODYNAMICS OF TIZANIDINE IN HEALTHY VOLUNTEERS
Yanting Wu
Favorite